Data collection extracted on a weekly basis week commencing 13 April 2020	Revised weekly data collection. The first collection is due week commencing 28 September 2020
All patients with defined long-term medical conditions which pose a COVID-19 risk, identified as clinically extremely vulnerable to that risk and/or on certain drug treatments as below:	All patients with defined long-term medical conditions which pose a COVID-19 risk, identified as clinically extremely vulnerable/potentially clinically vulnerable to that risk and/or on certain drug treatments as below:
Medical conditions that provide information on clinically extremely vulnerable patients • Severe asthma and dust related lung disease with relevant treatment in the last 12 months (asthma treatment & prednisolone OR high dose corticosteroid safety card) • COPD emphysema, and associated lung diseases with relevant treatment in the last 12 months (COPD drugs OR high dose corticosteroid safety card)	**Medical conditions that provide information on clinically extremely vulnerable patients** • Severe asthma and dust related lung disease with relevant treatment in the last 12 months (asthma treatment & prednisolone OR high dose corticosteroid safety card) • COPD emphysema, and associated lung diseases with relevant treatment in the last 12 months (COPD drugs OR high dose corticosteroid safety card)
• Non-asthma and non-COPD chronic respiratory disease • Cancer (haem and others) • Congenital heart disease • Genetic, metabolic or autoimmune disease • Immunosuppression drugs in the last 12 months • Flu-like symptoms or respiratory tract infections from 1 November 2019 • Transplants with severe Immunosuppression drug treatment in the last 12 months • Pregnant in last 9 months	• Non-asthma and non-COPD chronic respiratory disease • Cancer (haem and others) • Congenital heart disease • Genetic, metabolic or autoimmune disease • Immunosuppression drugs in the last 12 months • Flu-like symptoms or respiratory tract infections from 1 November 2019 • Transplants with severe Immunosuppression drug treatment in the last 12 months • Pregnant in last 9 months *(no change)*
• Patients designated separately as at risk from COVID-19 using high/medium/low risk SNOMED CT codes, for example	Patients designated separately as at risk from COVID-19 using high/medium/low risk SNOMED CT codes, for example *(no change)*
Patients with a COVID-19 activity code	Patients with a COVID-19 activity code *(no change)*
	Clinically vulnerable patients (eligible for seasonal flu vaccination) • Chronic respiratory disease • Unresolved asthma with recent asthma drug treatment (in the last 12 months) or has ever had an emergency hospital admission due to asthma • Chronic heart disease • Unresolved chronic kidney disease stage 3, 4 and 5 • Unresolved diabetes mellitus • Unresolved immunosuppression diagnosis • Immunosuppression procedure in the last 12 months • Chronic liver disease • Chronic neurological disease • Pregnant in the last 9 months (different cluster to clinically extremely vulnerable group) • In patients aged 16 and over: BMI of 40+ in the last 12 months • In patients aged 16 and over: Latest BMI in the last 3 years was 40+ • Learning disability (including Down's) • Has a 'requires flu vaccination' code • Identified as a healthcare worker in the last 12 months • Household contact of an immunocompromised individual
	Other potentially clinically vulnerable patients • Unresolved hypertension • Pulmonary hypertension • Dementia • Systemic lupus • Discoid and non-systemic lupus • Psoriasis • Rheumatoid arthritis and associated disorders
	Additional data items for patients from the above groups • Latest ethnic category code (all groups) • Earliest code indicating that the patient has died (all groups) • Latest smoking status (all groups) • Blood pressure from the last 2 years (all groups) • In patients aged 16 and over: all BMI and weight in the last 5 years plus latest height (all groups) • IFCC-HbA1c in the last 2 years (for diabetic patients in the flu group only) • Latest COPD resolved and admission codes (for COPD patients in the clinically extremely vulnerable group only) • ACE inhibitors, ARBs and non-steroidal anti-inflammatory drugs in the last 12 months (all groups) • Latest asthma emergency admission codes (for asthma patients in the flu group only) • Asthma-related drug treatments in the last 12 months (for asthma patients in the flu group only)